Trial Profile
Assessment of Physical Activity (PF10 Sub Domain of SF-36 Activity Score) and Tolerability in COPD Patients During Treatment With Spiriva Respimat.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jun 2014
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 26 Mar 2010 Actual patient number (1785) added as reported by ClinicalTrials.gov.
- 26 Mar 2010 Actual end date changed from Dec 2008 to January 2009 as reported by ClinicalTrials.gov.
- 05 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.